1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 29,000 | 29,600 | 11.12. | |
| 28,800 | 29,600 | 11.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.12. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 2 | GlobeNewswire (USA) | ||
| 01.12. | Spyre stock rating upgraded to Buy at Jones Trading on TL1A blockade potential | 2 | Investing.com | ||
| 07.11. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 04.11. | Spyre Therapeutics GAAP EPS of -$0.15 beats by $0.61 | 6 | Seeking Alpha | ||
| 04.11. | Spyre Therapeutics reports positive interim data for IBD drug SPY003 | 2 | Investing.com | ||
| 04.11. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody | 46 | GlobeNewswire (Europe) | SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (a4ß7 +... ► Artikel lesen | |
| 04.11. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 | 1 | GlobeNewswire (USA) | ||
| 15.10. | Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million | 1 | GlobeNewswire (USA) | ||
| 14.10. | Spyre Therapeutics Stock Rises 11% After $275 Mln Public Offering Pricing | 1 | RTTNews | ||
| 14.10. | Spyre Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.10. | Spyre Therapeutics prices public offering of 14.8M shares at $18.50 to raise $275M | 1 | Seeking Alpha | ||
| 14.10. | Spyre Therapeutics legt Preis für Aktienangebot auf 18,50 US-Dollar fest | 1 | Investing.com Deutsch | ||
| 14.10. | Spyre Therapeutics prices public offering at $18.50 per share | 2 | Investing.com | ||
| 14.10. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 13.10. | Spyre Therapeutics announces public offering of common stock and pre-funded warrants | 1 | Seeking Alpha | ||
| 13.10. | Spyre Therapeutics announces common stock offering | 1 | Investing.com | ||
| 13.10. | Spyre Therapeutics kündigt öffentliche Platzierung von Stammaktien an | 2 | Investing.com Deutsch | ||
| 13.10. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 27,600 | +6,98 % | Oruka Therapeutics appoints Chris Martin to board of directors | ||
| PALVELLA THERAPEUTICS | 85,50 | +3,64 % | Palvella Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und Kursziel von 190 US-Dollar | ||
| DIANTHUS THERAPEUTICS | 36,000 | +1,12 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results | Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy... ► Artikel lesen | |
| LENZ THERAPEUTICS | 24,510 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ) in South Korea for the Treatment of Presbyopia | SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 67,44 | -2,18 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants | SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ARCELLX | 72,69 | +0,99 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| AVIDITY BIOSCIENCES | 71,60 | +0,35 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| PRAXIS PRECISION MEDICINES | 267,28 | +2,18 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| IMMUNOVANT | 24,810 | 0,00 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| COGENT BIOSCIENCES | 40,040 | +2,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| QIAGEN | 38,605 | -1,34 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,70 | +0,47 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,070 | -3,70 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,420 | -1,37 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,020 | +3,79 % | Vera Therapeutics, Inc. - 8-K, Current Report |
Das Unternehmen SPYRE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 29,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.